SG127843A1 - Biomarker for response monitoring of cdk inhibitors in the clinic - Google Patents

Biomarker for response monitoring of cdk inhibitors in the clinic

Info

Publication number
SG127843A1
SG127843A1 SG200603415A SG200603415A SG127843A1 SG 127843 A1 SG127843 A1 SG 127843A1 SG 200603415 A SG200603415 A SG 200603415A SG 200603415 A SG200603415 A SG 200603415A SG 127843 A1 SG127843 A1 SG 127843A1
Authority
SG
Singapore
Prior art keywords
biomarker
clinic
cdk inhibitors
response monitoring
mammal
Prior art date
Application number
SG200603415A
Other languages
English (en)
Inventor
Wanda Eve Depinto
Xuefeng Yin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG127843A1 publication Critical patent/SG127843A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
SG200603415A 2005-05-25 2006-05-23 Biomarker for response monitoring of cdk inhibitors in the clinic SG127843A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68450205P 2005-05-25 2005-05-25

Publications (1)

Publication Number Publication Date
SG127843A1 true SG127843A1 (en) 2006-12-29

Family

ID=36954240

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200603415A SG127843A1 (en) 2005-05-25 2006-05-23 Biomarker for response monitoring of cdk inhibitors in the clinic

Country Status (9)

Country Link
US (1) US20060269482A1 (de)
EP (1) EP1726953B1 (de)
JP (1) JP2006325593A (de)
CN (1) CN101078716A (de)
AT (1) ATE405828T1 (de)
CA (1) CA2545426A1 (de)
DE (1) DE602006002311D1 (de)
ES (1) ES2313556T3 (de)
SG (1) SG127843A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114828B2 (en) 2007-04-16 2012-02-14 Honeywell International Inc. Azeotrope-like compositions of tetrafluoropropene and alcohols
WO2013071415A1 (en) * 2011-11-15 2013-05-23 University Health Network Targeting the rb pathway for the prevention of cancer
CN116240261B (zh) * 2023-02-22 2024-05-14 迈杰转化医学研究(苏州)有限公司 一种检测pbmc中shp2抑制剂活性的试剂盒及其方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4828752B2 (ja) * 1999-08-04 2011-11-30 株式会社医学生物学研究所 サイクリン／ｃｄｋ複合体のリン酸化酵素活性測定方法
US20030166016A1 (en) * 2000-04-28 2003-09-04 Foster Barbara A. Assay methods for cyclin dependent kinases
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives

Also Published As

Publication number Publication date
CN101078716A (zh) 2007-11-28
ATE405828T1 (de) 2008-09-15
ES2313556T3 (es) 2009-03-01
CA2545426A1 (en) 2006-11-25
EP1726953B1 (de) 2008-08-20
JP2006325593A (ja) 2006-12-07
EP1726953A1 (de) 2006-11-29
DE602006002311D1 (de) 2008-10-02
US20060269482A1 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
DK1745144T3 (da) Analysefremgangsmåde til opsporing af lægemidler på grundlag af in vitro-differentierede celler
BRPI0915619A2 (pt) métodos para determinar uma probabilidade de que um sujeito tenha contribuído com material genético para amostra de teste de material genético, para caracterizar amostra de teste de material genético e para determinar se uma pessoa de interesse contribuiu com material genético para uma amostra de teste de material genético, kit para análise de amostra de teste de material genético e sistema para determinar se um sujeito contribuiu com material genético para uma amostra
WO2007013575A3 (en) Method for diagnosing and treating renal cell carcinoma
CA2569599C (en) Method for the early detection of renal disease and injury
WO2007109571A3 (en) Methods of predicting and monitoring tyrosine kinase inhibitor therapy
DK1616184T3 (da) Fremgangsmåde og kit til at påvise tidlig begyndelse af renal tubulær cellebeskadigelse
NL1024869A1 (nl) Werkwijze en systeem voor het meten van voor ziekte relevante weefselveranderingen.
BRPI0518307A2 (pt) mÉtodo e composiÇço de matÉria para tratar um indivÍduo tendo um cÂncer, kit, composiÇço farmacÊutica, mÉtodo para impregnar ou carregar um dispositivo implantÁvel de liberaÇço de droga, dispositivo implantÁvel de liberaÇço de droga, mÉtodo para avaliar a resposta de um indivÍduo tendo cÂncer a um tratamento usando um agonista de tlr3 ou selecionar um indivÍduo tendo um cÂncer que responde a um tratamento usando um agonista de tlr3, complexo, mÉtodo para determinar se um composto de teste É étil para o tratamento de cÂncer, e, uso de um agonista de tlr3
WO2007146229A3 (en) Markers associated with arteriovascular events and methods of use thereof
WO2007044860A3 (en) Diabetes-associated markers and methods of use thereof
MX349622B (es) Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas.
BR112012031389A2 (pt) método para prever os resultados clínicos para pacientes com melanoma usando células de melanoma circulantes no sangue
DE602005016800D1 (de) Hif-prolylhydroxylase-aktivitätstest
ES2422735T3 (es) Procedimiento para la predicción de un riesgo de reacciones adversas a medicamentos mediante la determinación de HLA-B 1502
WO2007143211A3 (en) Methods for identifying agents and their use for the prevention of restenosis
JP2006311860A5 (de)
DK2201376T3 (da) En ny biomarkør til overvågning af udviklingen af sygdomme og vurdering af effektiviteten af terapier
MX2012003997A (es) Biomarcadores para predecir la sensibilidad y respuesta de enfermedades mediadas por proteina cinasa ck2 a inhibidores de ck2.
WO2008089135A3 (en) Identification of biomarkers predictive of dasatinib effects in cancer cells
CR20200394A (es) Métodos terapéuticos y diagnósticos para enfermedades inflrmatorias mediadas por mostocitos
SG127843A1 (en) Biomarker for response monitoring of cdk inhibitors in the clinic
EA201200603A1 (ru) Способ оценки жидкостного статуса пациента и/или чувствительности к удалению жидкости, контроллер и устройства
NZ594843A (en) Method or system using biomarkers for the monitoring of a treatment
WO2008012692A3 (en) Assay for efficacy of histone deacetylase inhibitors
SG11202108707WA (en) Methods and agents for assessing t-cell function and predicting response to therapy